Neoadjuvant nivolumab combo proved safe while yielding high response rates in patients with NSCLC.
A study found some mutations that are already targeted by approved or investigational drugs for prostate cancer, along with dozens of targets that should be considered as candidates for future trials.
In this video, Pashalina Kehagias discusses how an early increase in ctDNA may predict a poor response to regorafenib in advanced CRC.
AZD1775, a small-molecule, WEE1-targeting TKI, significantly shrunk tumors when administered in combination with cisplatin and docetaxel in a phase I trial.
In KEYNOTE-189, a pembrolizumab/chemo combination yielded OS and PFS benefits in patients with advanced NSCLC.
A 36-year-old woman presents with history of previous breast implants and induration of the left breast. What is your diagnosis?
In this video, Dr. Edison Liu describes a novel patient-derived xenograft platform that might enable development of a mouse-based clinical trials program.
A simple prognostic tool could be used to identify patients with HR-positive breast cancer who underwent 5 years of endocrine treatment and who might be at higher risk of late distant recurrence.
In this video, Dr. Elizabeth Swisher reviews the use of PARP inhibitors in ovarian cancer, and the importance of understanding how resistance to these agents develops.
A 38-year-old woman with a history of tobacco use presents with shortness of breath, cough, chest pain, and general malaise. What is your diagnosis?
Patients with alcohol-related HCC had worse OS than other HCC patients, mainly due to poorer liver function and more unfavorable tumor characteristics at diagnosis.
In this podcast, Dr. Debra Patt discusses trends in cancer care, including how treatments are becoming more personalized and less toxic.
In this video, Dr. Judd Moul discusses disparities in prostate cancer screening among African-American men, and the need for more research in this area.
Treatment with the TLR9 agonist CMP-001 appeared to potentially reverse resistance to immune checkpoint inhibition in patients with metastatic melanoma.
In the DUO and DYNAMO trials, duvelisib improved clinical responses in patients with R/R CLL/SLL and FL, respectively.